Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TUB-040 |
Synonyms | |
Therapy Description |
Limited information is currently available on TUB-040, a putative antibody-drug conjugate (ADC) targeting SLC34A2 (NAPI2B) (Mar 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TUB-040 | TUB040|TUB 040 | Limited information is currently available on TUB-040, a putative antibody-drug conjugate (ADC) targeting SLC34A2 (NAPI2B) (Mar 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06303505 | Phase Ib/II | TUB-040 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01) | Not yet recruiting | USA | 0 |